S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:ANGO

AngioDynamics - ANGO Stock Forecast, Price & News

$12.95
-0.22 (-1.67%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.89
$13.21
50-Day Range
$12.06
$15.48
52-Week Range
$11.71
$24.87
Volume
150,850 shs
Average Volume
380,921 shs
Market Capitalization
$506.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.50

AngioDynamics MarketRank™ Forecast

Analyst Rating
Strong Buy
4.00 Rating Score
Upside/​Downside
120.1% Upside
$28.50 Price Target
Short Interest
Healthy
3.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.27mentions of AngioDynamics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$59,997 Sold Last Quarter
Proj. Earnings Growth
1,000.00%
From $0.01 to $0.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

379th out of 1,026 stocks

Surgical & Medical Instruments Industry

37th out of 104 stocks

ANGO stock logo

About AngioDynamics (NASDAQ:ANGO) Stock

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

ANGO Stock News Headlines

Predict These Market Breakouts with A.I.
We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. pixel
ANGO.N - | Stock Price & Latest News | Reuters
Predict These Market Breakouts with A.I.
We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. pixel
Earnings Preview For AngioDynamics
AngioDynamics: Fiscal Q2 Earnings Snapshot
Here's Why This Hidden Growth Stock Is a Buy
See More Headlines
Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

ANGO Company Calendar

Last Earnings
1/05/2023
Today
2/09/2023
Next Earnings (Estimated)
4/06/2023
Fiscal Year End
5/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ANGO
CUSIP
03475V10
Employees
800
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$28.50
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+120.1%
Consensus Rating
Strong Buy
Rating Score (0-4)
4.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,550,000.00
Pretax Margin
-10.79%

Debt

Sales & Book Value

Annual Sales
$327.93 million
Cash Flow
$0.75 per share
Book Value
$10.96 per share

Miscellaneous

Free Float
37,216,000
Market Cap
$506.79 million
Optionable
Optionable
Beta
0.63

Social Links


Key Executives

  • James Christopher Clemmer
    President, Chief Executive Officer & Director
  • David D. HelselDavid D. Helsel
    SVP-Global Operations, Research & Development
  • Stephen A. TrowbridgeStephen A. Trowbridge
    Chief Financial Officer & Executive Vice President
  • Kim L. Seabury
    Senior Vice President-Information Technology
  • Juan Carlos Serna
    Senior VP-Scientific & Clinical Affairs













ANGO Stock - Frequently Asked Questions

Should I buy or sell AngioDynamics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" ANGO shares.
View ANGO analyst ratings
or view top-rated stocks.

What is AngioDynamics' stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year target prices for AngioDynamics' stock. Their ANGO share price forecasts range from $22.00 to $35.00. On average, they anticipate the company's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price.
View analysts price targets for ANGO
or view top-rated stocks among Wall Street analysts.

How have ANGO shares performed in 2023?

AngioDynamics' stock was trading at $13.77 at the beginning of the year. Since then, ANGO stock has decreased by 6.0% and is now trading at $12.95.
View the best growth stocks for 2023 here
.

When is AngioDynamics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 6th 2023.
View our ANGO earnings forecast
.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) announced its earnings results on Thursday, January, 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The medical instruments supplier earned $85.43 million during the quarter, compared to analyst estimates of $84.05 million. AngioDynamics had a negative net margin of 9.98% and a negative trailing twelve-month return on equity of 0.14%.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics updated its FY23 earnings guidance on Thursday, January, 5th. The company provided EPS guidance of $0.01-0.06 for the period, compared to the consensus estimate of $0.01. The company issued revenue guidance of $342-346 million, compared to the consensus revenue estimate of $342.48 million.

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Heartland Advisors Inc. (1.56%), Paradigm Capital Management Inc. NY (0.91%), Lapides Asset Management LLC (0.55%), Assenagon Asset Management S.A. (0.37%), Allspring Global Investments Holdings LLC (0.32%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.25%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends
.

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $12.95.

How much money does AngioDynamics make?

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $506.73 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does AngioDynamics have?

The company employs 800 workers across the globe.

Does AngioDynamics have any subsidiaries?
The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.
Read More
How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.

This page (NASDAQ:ANGO) was last updated on 2/9/2023 by MarketBeat.com Staff